DNA repair inhibitors: the next major step to improve cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Cancer therapies like radiation and chemotherapy damage DNA to halt cancer cell proliferation.
• Cancer cells develop resistance to these treatments by activating DNA repair pathways, such as base excision repair (BER) and nucleotide excision repair (NER).
• Targeting DNA repair mechanisms is crucial for enhancing cancer therapy efficacy and overcoming drug resistance.

Purpose of the Study:

• To review known inhibitors of Excision Repair Cross-Complementation Group 1 (ERCC1) and DNA polymerase beta (pol β).
• To provide an overview of the discovery efforts for these specific DNA repair protein inhibitors.
• To identify potential drug candidates for improving existing cancer treatments.

Main Methods:

• Literature review of inhibitors targeting ERCC1 and DNA polymerase beta (pol β).
• Analysis of the role of ERCC1 in NER and pol β in BER.
• Summarization of drug discovery efforts for these targets.

Main Results:

• Over sixty inhibitors have been identified for DNA polymerase beta (pol β).
• Very few inhibitors have been discovered for ERCC1.
• ERCC1 is a key component of NER, while pol β is an error-prone polymerase in BER.

Conclusions:

• Targeting ERCC1 and pol β offers a promising strategy to sensitize cancer cells to DNA-damaging agents.
• Further research into ERCC1 inhibitors is needed to match the progress seen with pol β inhibitors.
• Developing novel inhibitors for these pathways could significantly improve outcomes for patients with relapsed or drug-resistant cancers.